Molecular oncology

Molecular Oncology. Causes of Cancer and Targets for Treatment-CUP (2014)

Molecular oncology. Causes of cancer and targets for treatment. Eds Edward P. Gelmann et al., Cambridge University Press (2014)

 — Русский


Part 1.1. Analytical techniques: analysis of DNA »

  1. Cancer genome sequencing
  2. Genome-wide association studies of cancer predisposition
  3. Comparative genomic hybridization
  4. Chromosome analysis: molecular cytogenetic approaches
  5. DNA methylation

Part 1.2 Analytical techniques: analysis of RNA »

  1. The application of high-throughput analyses to cancer diagnosis and prognosis
  2. Cancer proteomics
  3. Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer
  4. In situ techniques for protein analysis in tumor tissue

Part 2.1. Molecular pathways underlying carcinogenesis: signal transduction »

  1. HER
  2. The insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology
  3. TGF signaling in stem cells and tumorigenesis
  4. Platelet-derived growth factor
  5. FMS-related tyrosine kinase 3
  6. ALK: Anaplastic lymphoma kinase
  7. The FGF signaling axis in prostate tumorigenesis
  8. Hepatocyte growth factor/Met signaling in cancer
  9. PI3K
  10. Intra-cellular tyrosine kinase
  11. WNT signaling in neoplasia
  12. Ras
  13. BRAF mutations in human cancer: biologic and therapeutic implications
  14. Aurora kinases in cancer: an opportunity for targeted therapy
  15. 14-3-3 proteins in cancer
  16. STAT signaling as a molecular target for cancer therapy
  17. The MYC oncogene family in human cancer
  18. Jun proteins and AP-1 in tumorigenesis
  19. Forkhead box proteins: the tuning forks in cancer development and treatment
  20. NF-kB and cancer

Part 2.2. Molecular pathways underlying carcinogenesis: apoptosis »

  1. Apoptosis: the extrinsic pathway
  2. Apoptosis: the intrinsic pathway

Part 2.3. Molecular pathways underlying carcinogenesis: nuclear receptors »

  1. Androgens and the androgen receptor (AR)
  2. Emerging roles of peroxisome proliferator-activated receptor gamma in cancer

Part 2.4. Molecular pathways underlying carcinogenesis: DNA repair »

  1. The ATM-mediated DNA damage response
  2. Werner syndrome: association of premature aging and cancer predisposition
  3. Hereditary disorders of DNA repair and DNA damage tolerance that predispose to neoplastic transformation
  4. Telomerase: target for cancer treatment

Part 2.5. Molecular pathways underlying carcinogenesis: cell cycle »

  1. Cell cycle: mechanisms of control and dysregulation in cancer
  2. DNA damage-induced apoptosis

Part 2.6. Molecular pathways underlying carcinogenesis: other pathways »

  1. The ubiquitin/proteasome pathway in neoplasia
  2. Small silencing non-coding RNAs: cancer connections and significance

Part 3.1. Molecular pathology: carcinomas »

  1. Head and neck cancer
  2. Lung cancer
  3. Esophageal cancer
  4. Gastric cancer
  5. Small-bowel tumors: molecular mechanisms and targeted therapy
  6. Colon and rectal cancer
  7. Pancreatic cancer
  8. Hepatocellular carcinoma
  9. Renal cell carcinomas
  10. Bladder cancer
  11. Prostate cancer
  12. Targeted therapies in breast cancer
  13. Molecular targets for epithelial ovarian cancer
  14. Testicular cancer: germ-cell tumors (GCT)
  15. Cervical cancer

Part 3.2. Molecular pathology: cancers of the nervous system »

  1. Brain tumors
  2. Mechanisms of pituitary tumorigenesis
  3. Molecular oncology of neuroblastoma
  4. Neurofibromatosis type I

Part 3.3. Molecular pathology: cancers of the skin »

  1. Squamous-cell carcinoma
  2. Molecular oncology of basal cell carcinomas
  3. Melanoma

Part 3.4. Molecular pathology: endocrine cancers »

  1. Oncogenic events and therapeutic targets in thyroid cancer
  2. The parathyroid glands
  3. Multiple endocrine neoplasia type 2 (MEN2)

Part 3.5. Molecular pathology: adult sarcomas »

  1. Sarcomas

Part 3.6. Molecular pathology: lymphoma and leukemia »

  1. Molecular pathology of lymphoma
  2. The molecular basis of acute myeloid leukemia
  3. Molecular oncology of acute promyelocytic leukemia (APL)
  4. Acute lymphoblastic leukemia (ALL)
  5. B-cell chronic lymphocytic leukemia
  6. Chronic myeloid leukemia: imatinib and next-generation ABL inhibitors
  7. Multiple myeloma
  8. EMS: the 8p11 myeloproliferative syndrome
  9. JAK2 and myeloproliferative neoplasms

Part 3.7. Molecular pathology: pediatric solid tumors »

  1. Pediatric solid tumors: disorders of suppressor genes

Part 4. Pharmacologic targeting of oncogenic pathways »

  1. Oncology drug discovery for biologics: antibody development strategies and considerations
  2. Targeting the EGFR family of receptor tyrosine kinases
  3. Therapeutic approaches with antibodies to cell-surface receptors
  4. Signal transduction in tumor angiogenesis
  5. Tyrosine-kinase inhibitors in oncology
  6. Anti-estrogens and selective estrogen-receptor modulators
  7. Therapeutic applications of anti-sense mechanisms for the treatment of cancer
  8. Induction of apoptosis
  9. DNA-methylation inhibitors
  10. Histone deacetylase inhibitor
  11. Drug resistance, complex and diverse: ABC transporters as an example
  12. Molecular profiling and therapeutic decision-making: the promise of personalized medicine
  13. DNA repair inhibition in anti-cancer therapeutics

 

https://yadi.sk/d/gDwTahCjnu8Gg

0

Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *